Skip Nav Destination
Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial
Development of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosis
Population dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
